Cargando…

Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes

In the present study, we investigated the therapeutic potential of a selective S1P(1) receptor modulator, ponesimod, to protect and reverse autoimmune diabetes in non-obese diabetic (NOD) mice. Ponesimod was administered orally to NOD mice starting at 6, 10, 13 and 16 weeks of age up to 35 weeks of...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Sylvaine, Piali, Luca, Kuhn, Chantal, Steiner, Beat, Sauvaget, Virginia, Valette, Fabrice, Clozel, Martine, Bach, Jean-François, Chatenoud, Lucienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811978/ https://www.ncbi.nlm.nih.gov/pubmed/24204793 http://dx.doi.org/10.1371/journal.pone.0077296

Ejemplares similares

Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013)

The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4(+) T cells
por: Besançon, Alix, et al.
Publicado: (2017)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance
por: Baas, Marije, et al.
Publicado: (2016)

Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target
por: You, Sylvaine, et al.
Publicado: (2009)

Therapeutic Targeting of B Cells and T Cells in Autoimmune Diabetes: Is It a Solution?
por: Chatenoud, Lucienne
Publicado: (2013)

Modulation of autoimmune diabetes by N-ethyl-N-nitrosourea- induced mutations in non-obese diabetic mice
por: Chatenoud, Lucienne, et al.
Publicado: (2022)

Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes
por: Candon, Sophie, et al.
Publicado: (2015)

Correction: Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes
por: Candon, Sophie, et al.
Publicado: (2016)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties
por: Piali, Luca, et al.
Publicado: (2017)

Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans
por: Jurcevic, Stipo, et al.
Publicado: (2016)

Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P(1)‐selective modulation
por: Kihara, Yasuyuki, et al.
Publicado: (2022)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice
por: Zhu, Zhihui, et al.
Publicado: (2023)

The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes
por: Mondanelli, Giada, et al.
Publicado: (2017)

Targeting activated T cells in type I diabetes and islet transplantation
por: Chatenoud, Lucienne
Publicado: (2011)

The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells
por: Safaeinejad, Fahimeh, et al.
Publicado: (2021)

IL-4 and IL-17 Are Required for House Dust Mite-Driven Airway Hyperresponsiveness in Autoimmune Diabetes-Prone Non-Obese Diabetic Mice
por: Foray, Anne-Perrine, et al.
Publicado: (2021)

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
por: Valenzuela, Belén, et al.
Publicado: (2022)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
por: Grinberg-Bleyer, Yenkel, et al.
Publicado: (2010)

Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
por: Staeva, Teodora P., et al.
Publicado: (2013)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies
por: Freedman, Mark S., et al.
Publicado: (2022)

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ET(A) Versus ET(B) Receptors and on the Functionality of Endothelial ET(B) Receptors
por: Iglarz, Marc, et al.
Publicado: (2015)

Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases
por: Bach, Jean-François
Publicado: (2002)

The reversible P2Y(12) antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat
por: Rey, Markus, et al.
Publicado: (2017)

Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells
por: Calderon, Damelys, et al.
Publicado: (2012)

MicroRNA-146a-deficient mice develop immune complex glomerulonephritis
por: Amrouche, Lucile, et al.
Publicado: (2019)

Inducing and Administering Tregs to Treat Human Disease
por: Perdigoto, Ana Luisa, et al.
Publicado: (2016)

Revisiting the Hygiene Hypothesis in the Context of Autoimmunity
por: Bach, Jean-François
Publicado: (2021)

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity
por: Garo, Lucien P., et al.
Publicado: (2019)

Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
por: Deligne, Claire, et al.
Publicado: (2022)

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
por: Gatfield, John, et al.
Publicado: (2012)

ZnT8 Is a Major CD8(+) T Cell–Recognized Autoantigen in Pediatric Type 1 Diabetes
por: Énée, Émmanuelle, et al.
Publicado: (2012)

Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune Diabetes
por: Corcos, Noémie, et al.
Publicado: (2021)

Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections
por: Dellière, Sarah, et al.
Publicado: (2018)

The DYF-5 RCK and CDKL-1 CDKL5 kinases contribute differentially to shape distinct sensory neuron cilia morphologies in C. elegans
por: Maurya, Ashish Kumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_073as0nmcl74puhuaes6nriqir